Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its pipeline with a focus on unmet medical needs, as highlighted in a recent appearance on The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage. According to Durkacz, this area remains underserved by currently available treatments.
The company's commercial alcohol metabolism product, unbuzzd™, is currently available in the U.S. market and is designed to accelerate blood alcohol metabolism. Quantum retains a 19.84% stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), as of March 31, 2026, and receives royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity. This agreement provides Quantum with a recurring revenue stream from a product already on the market.
Looking ahead, Quantum BioPharma is preparing for its upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models, targeting the underlying mechanism of multiple sclerosis. The advancement to Phase 2 marks a critical step toward addressing a significant unmet need in neurodegenerative disease.
The company's focus on both innovative therapies and commercial products positions it to potentially impact patients and the biopharmaceutical industry. If successful, Lucid-MS could offer a new treatment option for the approximately 2.8 million people worldwide living with multiple sclerosis, many of whom experience progressive mobility loss. The Phase 2 trial results will be closely watched by investors and the medical community.
For more information on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM. The full press release is available at https://ibn.fm/HURxt.
